Evidence map›Paper›PMID 27128797›Full record

ArticlePLoS pathogens2016

Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections.

Jian-Da Lin, Ningguo Feng, Adrish Sen, Murugabaskar Balan, Hsiang-Chi Tseng, Constance McElrath, Sergey V Smirnov, Jianya Peng, Linda L Yasukawa, Russell K Durbin and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 127 papers.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 190 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Microbiota-dependent IFN-L controls uterine and placental immunity.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Interferon-Based Therapeutics in Cancer Therapy: Past, Present, and Future.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jian-Da LinDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Ningguo FengStanford University, Stanford, California, United States of America.
Adrish SenStanford University, Stanford, California, United States of America.
Murugabaskar BalanDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Hsiang-Chi TsengDepartment of Pathology and Laboratory Medicine, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Constance McElrathDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Sergey V SmirnovDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Jianya PengDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Linda L YasukawaStanford University, Stanford, California, United States of America.
Russell K DurbinCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Joan E DurbinDepartment of Pathology and Laboratory Medicine, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Harry B GreenbergStanford University, Stanford, California, United States of America.
Sergei V KotenkoDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Rutgers, Newark, New Jersey, United States of America.
Rutgers, The State University of New Jersey · USRutgers HealthStanford University · USVA Palo Alto Health Care System · US

Funding

Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune ProfilingU01AI089859 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2010 to 2015
$33.8M
Development of IFN-lambda3 for the Prevention and Treatment of Virus InfectionR01AI104669 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI DURBIN, JOAN E., KOTENKO, SERGEI V · 2013 to 2017
$5.9M
VIRAL GASTROENTERITIS--BASIS OF PROTECTION AND VIRULENCER01AI021362 · NIAID · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 1989 to 2014
$5.4M
Role of Interferon-lambda in Antiviral ResponseR01AI057468 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KOTENKO, SERGEI V · 2005 to 2009
$1.9M
Viral Gastroenteritis: Basis of Virulence and ProtectionR56AI021362 · NIAID · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI GREENBERG, HARRY BERNARD · 2015 to 2015
$506k
BLRD VA I01 BX000158NIAID NIH HHS R01 AI021362NIAID NIH HHS R01 AI057468NIAID NIH HHS R01 AI104669NIAID NIH HHS R56 AI021362NIAID NIH HHS U01 AI089859
6 · The paper itself

Abstract

Type I (IFN-α/β) and type III (IFN-λ) interferons (IFNs) exert shared antiviral activities through distinct receptors. However, their relative importance for antiviral protection of different organ systems against specific viruses remains to be fully explored. We used mouse strains deficient in type-specific IFN signaling, STAT1 and Rag2 to dissect distinct and overlapping contributions of type I and type III IFNs to protection against homologous murine (EW-RV strain) and heterologous (non-murine) simian (RRV strain) rotavirus infections in suckling mice. Experiments demonstrated that murine EW-RV is insensitive to the action of both types of IFNs, and that timely viral clearance depends upon adaptive immune responses. In contrast, both type I and type III IFNs can control replication of the heterologous simian RRV in the gastrointestinal (GI) tract, and they cooperate to limit extra-intestinal simian RRV replication. Surprisingly, intestinal epithelial cells were sensitive to both IFN types in neonatal mice, although their responsiveness to type I, but not type III IFNs, diminished in adult mice, revealing an unexpected age-dependent change in specific contribution of type I versus type III IFNs to antiviral defenses in the GI tract. Transcriptional analysis revealed that intestinal antiviral responses to RV are triggered through either type of IFN receptor, and are greatly diminished when receptors for both IFN types are lacking. These results also demonstrate a murine host-specific resistance to IFN-mediated antiviral effects by murine EW-RV, but the retention of host efficacy through the cooperative action by type I and type III IFNs in restricting heterologous simian RRV growth and systemic replication in suckling mice. Collectively, our findings revealed a well-orchestrated spatial and temporal tuning of innate antiviral responses in the intestinal tract where two types of IFNs through distinct patterns of their expression and distinct but overlapping sets of target cells coordinately regulate antiviral defenses against heterologous or homologous rotaviruses with substantially different effectiveness.

Indexed as

AnimalsAnimals, NewbornDisease Models, AnimalEnzyme-Linked Immunosorbent AssayHumansImmunoblottingImmunohistochemistryInterferon-gammaInterferon Type IIntestinesMiceMice, Inbred C57BLMice, KnockoutPolymerase Chain ReactionRotavirusRotavirus InfectionsInterferon-gammaInterferon Type I

Identifiers

PMID27128797
PMCPMC4851417
OpenAlexW2288694532

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.